[{"orgOrder":0,"company":"Intrinsic Medicine","sponsor":"Phoenix Biotech Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2022","type":"Termination","leadProduct":"2-Fucosyllactose-Synthetic","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Intrinsic Medicine","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Intrinsic Medicine \/ Phoenix Biotech Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"Intrinsic Medicine \/ Phoenix Biotech Acquisition Corp."},{"orgOrder":0,"company":"Intrinsic Medicine","sponsor":"Phoenix Biotech Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2022","type":"Merger","leadProduct":"2-Fucosyllactose-Synthetic","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Intrinsic Medicine","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Intrinsic Medicine \/ Phoenix Biotech Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"Intrinsic Medicine \/ Phoenix Biotech Acquisition Corp."}]

Find Clinical Drug Pipeline Developments & Deals for 2-Fucosyllactose-Synthetic

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : OM002 is a synthetic biology-produced human milk oligosaccharide (HMO) 2’-fucosyllactose, or 2’FL. The single most abundant HMO is 2’FL, which constitutes nearly 30% of the total HMO proportion in human milk.

                          Brand Name : OM002

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 06, 2022

                          Lead Product(s) : 2-Fucosyllactose-Synthetic

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II

                          Sponsor : Phoenix Biotech Acquisition Corp.

                          Deal Size : $136.0 million

                          Deal Type : Termination

                          blank

                          02

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Anticipated cash resources will fund a Phase 2b clinical trial of Intrinsic’s lead, HMO-based drug candidate, OM002 (2’-fucosyllactose, or 2’FL), in over 400 patients with the constipation dominant form of irritable bowel syndrome (IBS-C).

                          Brand Name : OM002

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 31, 2022

                          Lead Product(s) : 2-Fucosyllactose-Synthetic

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II

                          Sponsor : Phoenix Biotech Acquisition Corp.

                          Deal Size : $136.0 million

                          Deal Type : Merger

                          blank